Bordron, A.; Morel, M.; Bagacean, C.; Dueymes, M.; Pochard, P.; Harduin-Lepers, A.; Jamin, C.; Pers, J.-O.
Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases. Int. J. Mol. Sci. 2021, 22, 3402.
https://doi.org/10.3390/ijms22073402
AMA Style
Bordron A, Morel M, Bagacean C, Dueymes M, Pochard P, Harduin-Lepers A, Jamin C, Pers J-O.
Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases. International Journal of Molecular Sciences. 2021; 22(7):3402.
https://doi.org/10.3390/ijms22073402
Chicago/Turabian Style
Bordron, Anne, Marie Morel, Cristina Bagacean, Maryvonne Dueymes, Pierre Pochard, Anne Harduin-Lepers, Christophe Jamin, and Jacques-Olivier Pers.
2021. "Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases" International Journal of Molecular Sciences 22, no. 7: 3402.
https://doi.org/10.3390/ijms22073402
APA Style
Bordron, A., Morel, M., Bagacean, C., Dueymes, M., Pochard, P., Harduin-Lepers, A., Jamin, C., & Pers, J.-O.
(2021). Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases. International Journal of Molecular Sciences, 22(7), 3402.
https://doi.org/10.3390/ijms22073402